Phaseline

Targets › SRD5A1

SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1): drug programs, companies and trials

4 programs from 4 companies in 19 trials: 15 Phase 2, 3 Phase 3, 1 Phase 4; Oncology; next expected readout Nov 2026.

Catalyzes the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms. Converts testosterone into 5-alpha-dihydrotestosterone (DHT), a more potent androgen as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male sexual…. (UniProt, P18405)

Open in Phaseline: the race on SRD5A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Turku University HospitalDutasteride
Steroid 5-alpha-reductase inhibitor
SRD5A1, SRD5A2, SRD5A3Phase 4Prostatic HyperplasiaDec 2026
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairAbiraterone
Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist; Steroid 5-alpha-reductase inhibitor
CYP17A1, AR, SRD5A1, SRD5A2, SRD5A3Phase 2Prostate Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Castration Levels of Testosterone; Advanced Prostate Adenocarcinoma …Nov 2026
Radboud University Medical CenterDutasteride
Steroid 5-alpha-reductase inhibitor
SRD5A1, SRD5A2, SRD5A3Phase 2Salivary Duct CarcinomaSep 2027
Paul TorenDutasteride
Steroid 5-alpha-reductase inhibitor
SRD5A1, SRD5A2, SRD5A3Phase 2Bladder CancerApr 2030

Conditions

Prostate Cancer (6) Metastatic Prostate Cancer (2) Prostatic Hyperplasia (1) Bladder Cancer (1) Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) Castration Levels of Testosterone (1) Advanced Prostate Adenocarcinoma (1) Prostate Cancer (Diagnosis) (1) Metastatic Castration-resistant Prostate Cancer (1) Prostate Cancer Metastatic Disease (1) Salivary Gland Carcinoma (1) Prostate Carcinoma (1)

Modalities

small molecule (4)

Companies

Turku University Hospital (1) Paul Toren (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) Radboud University Medical Center (1)

Related targets

SRD5A2 (4) SRD5A3 (4) CYP17A1 (1) AR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.